Developing aerosol treatments for drug-resistant tuberculosis
Biomimetic Peptide Aerosols for Rapid Clearance of Pulmonary MDR Tuberculosis
This study is testing a new spray treatment that could help people with multidrug-resistant tuberculosis (MDR-TB) get better faster by working with current antibiotics to clear the infection from their lungs more effectively and with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pennsylvania State University, the NIH-funded |
| Lab location | 1 site (University Park, United States) |
| Project ID | NIH-10974024 on NIH RePORTER |
What this research studies
This research focuses on creating a new type of aerosol treatment designed to rapidly eliminate multidrug-resistant tuberculosis (MDR-TB) from the lungs. By using engineered peptides that can self-assemble and target the bacteria, the treatment aims to work alongside existing antibiotics to shorten the lengthy treatment duration typically required for TB. The approach is innovative, as it seeks to enhance the effectiveness of current therapies while minimizing side effects. Patients may benefit from a more efficient and less burdensome treatment regimen.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multidrug-resistant tuberculosis who require effective treatment options.
Not a fit: Patients with drug-sensitive tuberculosis or those who do not have tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the treatment time for patients with MDR-TB, improving adherence and outcomes.
How similar studies have performed: Previous research has shown promise in using similar biomimetic approaches to enhance antibiotic efficacy, indicating potential for success in this novel application.
Where this research is happening
University Park, United States
- Pennsylvania State University, the — University Park, United States (Active)
Researchers
- Principal investigator: Medina, Scott Hammond — Pennsylvania State University, the
- Study coordinator: Medina, Scott Hammond
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.